Beyond thrombosis: the impact of tissue factor signaling in cancer

Dusten Unruh and Craig Horbinski

Abstract

Tissue factor (TF) is the primary initiator of the coagulation cascade, though its effects extend well beyond hemostasis. When TF binds to Factor VII, the resulting TF:FVIIa complex can proteolytically cleave transmembrane G protein-coupled protease-activated receptors (PARs). In addition to activating PARs, TF:FVIIa complex can also activate receptor tyrosine kinases (RTKs) and integrins. These signaling pathways are utilized by tumors to increase cell proliferation, angiogenesis, metastasis, and cancer stem-like cell maintenance. Herein, we review in detail the regulation of TF expression, mechanisms of TF signaling, their pathological consequences, and how it is being targeted in experimental cancer therapeutics.

Keywords: Tissue factor, Protease-activated receptors, Receptor tyrosine kinases, Integrins, Metastasis, Angiogenesis

Introduction

Tissue factor (TF), also named Factor III, CD142, or thromboplastin, is a transmembrane glycoprotein that participates in the rate-limiting step of the coagulation cascade. It derives its name from the ability of tissue extracts from platelets, leukocytes, and organs to clot blood. Morawitz is credited with developing the "classical" theory of blood coagulation in 1905, wherein prothrombin is converted into thrombin when incubated with tissue extracts and calcium [1]. He postulated that components for blood clotting are always present in circulating blood, except for TF (then named thrombokinase), which must be released from tissues [2]. Thirty years later, Howell used the term "Tissue Factor" to describe an extract from tissues that promotes coagulation [3]. TF is constitutively expressed in the subendothelial spaces and adventitia, where it acts as a hemostatic envelope to halt bleeding when it encounters calcium and coagulation factors. TF is abundantly expressed in highly vascularized organs, like the brain, lungs, placenta, heart, and kidneys [4, 5]. During vascular injury, TF is exposed to the blood, where it functions as a cofactor for the circulating zymogen factor VII (FVII). This TF:FVIIa complex can then bind and activate either factor IX (FIX) or factor X (FX), triggering a cascade that generates fibrin and activates platelets, resulting in a hemostatic plug at the site of injury.

TF is highly expressed in many types of cancer [6], and cancer cells can shed TF-active microvesicles (TF-MVs) into the circulation [7]. Not surprisingly, many cancers cause venous thromboembolism (VTE), with high levels of fTF-MVs correlating with increased VTE risk [8]. As a group, cancer patients have an ~ 6-fold increased risk of VTE compared to the general population [9–11]. This paraneoplastic event is called “Trousseau Syndrome,” named after the French physician Armand Trousseau, who was among the first to describe this in the 19th century in his cancer patients [12]. (He also developed VTE himself in 1867 and correctly diagnosed himself with fatal gastric cancer.)

It is now clear, however, that TF has other major roles beyond hemostasis and thrombosis. Ancient organisms like the horseshoe crab (Limulus polyphemus) use proteins similar to TF as an immune response to entrap pathogens [13]. Indeed, many components of the mammalian coagulation system share similarities with...
inflammatory molecules of the immune system, and that, in addition to coagulation, they play important roles in immunity and wound healing [13]. Cancers can use these TF-activated pathways to enhance cell proliferation, cell survival, angiogenesis, metastasis, and cancer stem-like cell (CSC) maintenance. In fact, because of these similarities to wound healing, cancer has been called “the wound that does not heal” [14].

Herein, we present a general overview of the mechanisms controlling TF expression in cancer, discuss TF-mediated signaling pathways, highlight how TF controls cancer progression, and review TF-targeted therapeutic strategies being tested to improve cancer management.

**TF structure and isoforms**

TF is encoded by *F3*, a 12.5 kb gene located on chromosome 1p21.3. This gene contains 6 exons that can produce two different proteins. One protein, the product of all 6 exons, is full-length TF (flTF). The other is an alternatively spliced isoform, termed asTF (Fig. 1). These two proteins have an apparent molecular mass of ~47 kDa and ~26 kDa, respectively, after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [15, 16].

Human flTF is a 263 amino acid transmembrane glycoprotein that is comprised of an extracellular domain (residues 1-219), a transmembrane domain (residues 220-242), and an intracellular C-terminal domain (residues 243-263). This portion of TF is structurally homologous to class II cytokine receptors [17, 18]. The extracellular portion of flTF contains two fibronectin type III domains and two disulfide bridges at Cys<sup>49</sup>–Cys<sup>57</sup> and Cys<sup>186</sup>–Cys<sup>209</sup> [19]. Although the extracellular domain of TF is structurally similar to the class II cytokine receptors, it does not bind to any cytokines. Instead, it binds to coagulation factor VII (FVII) zymogen. The cytoplasmic C-terminal domain of flTF does not contain any significant homology with other proteins, and it lacks adaptor motifs usually found in the cytokine receptor superfamily that bind with Janus kinase-signal transducer and activator of transcription (JAK-STAT) effectors. Instead, TF’s cytoplasmic C-terminal domain interacts with a variety of scaffolding and adapter proteins that influence cytoskeletal structure and cell signaling.

In 2003, Bogdanov et al. first described asTF, in which exon 5 is spliced out and exons 4 and 6 are fused together. This causes a shift in the open reading frame that produces a unique 40 amino acid C-terminus [15]. The unique C-terminus of asTF lacks a transmembrane domain and is secreted. Although asTF retains a Lys<sup>165</sup> and

![Fig. 1](image-url)
Lys<sup>466</sup> doublet, which is required for TF:FVIIa complex formation, its procoagulant activity is questionable, as it lacks a complete binding site for coagulation factors IX and X [15]. Indeed, αsTF has minimal to no procoagulant activity when compared to fITF in vitro [20–22]. However, these studies were primarily conducted in fITF deficient conditions, and αsTF may indirectly trigger coagulation [23, 24]. Even so, Ünlü et al. observed that αsTF does not affect receptor-ligand kinetics of fITF on endothelial cells [21]. Because of αsTF’s positively charged C-terminus, it likely requires a negatively charged phospholipid membrane to promote coagulation, which is often found in cancer.

In addition to alternative splicing, TF can undergo post-translational modifications. The extracellular domain has three N-linked glycosylation sites (Asn<sup>11</sup>, Asn<sup>124</sup>, and Asn<sup>137</sup>), and TF glycosylation may affect the charge of TF and its affinity to FVII [25, 26]. It has widely been assumed that recombinant TF and naturally occurring TF are identical, but Krudysz-Amblo et al. showed that TF derived from the placenta was 5-fold more procoagulant than recombinant TF and that this difference was due to increased glycosylation of placental TF [27]. Phosphorylation is another post-translational modification that affects TF signaling, discussed below. The C-terminus of TF contains two phosphorylation sites (Ser<sup>253</sup> and Ser<sup>258</sup>) [28]. TF can also undergo palmitoylation, the covalent attachment of fatty acid palmitate to a cysteine (S-palmitoylation) or, less frequently, to threonine or serine (O-palmitoylation) [29]. Palmitoylation controls a wide variety of cellular functions, including protein subcellular trafficking, protein stability, and protein-protein interactions [29]. The intracellular domain of TF has one S-palmitoylation site (Cys<sup>245</sup>) [30], which suppresses phosphorylation of Ser<sup>258</sup> in the TF C-terminus [31]. However, the extent of TF palmitoylation, and whether it influences plasma membrane microdomain trafficking, is still unclear.

**Noncoagulant signaling by tissue factor**

Although TF is classified as a cytokine class II receptor, its signaling mechanism differs greatly from that family of receptors. TF can trigger both proteolytic and non-proteolytic cell signaling, and both TF isoforms have unique mechanisms of action (Fig. 2). On tumor cells, fITF binds the inactive zymogen, FVII, forming a fITF:FVII complex in which FVII is rapidly converted into an active protease, FVIIa. The fITF:FVIIa complex then binds and activates FX, creating a ternary fITF:FVIIa:FXa complex. This complex cleaves several protease-activated receptors (PARs), which belong to the seven-transmembrane G protein-coupled receptor family whose members are irreversibly activated by proteolytic cleavage of the N-terminus. Cleavage of the N-terminus on PAR releases its tethered ligand, allowing it to fold back on itself and bind to the extracellular portion of loop 2, in turn altering the binding affinity of PAR to intracellular heterotrimeric G proteins. These G proteins are composed of three unique subunits, α, β, and γ, and act as molecular switches inside cells to initiate a remarkably diverse array of functions.

To date, the PAR group of receptors consists of PAR1, PAR2, PAR3, and PAR4. TF activation of the coagulation cascade generates thrombin, and PAR1 was first discovered in 1991 as a receptor for thrombin on platelets [32]. PAR1, PAR3, and PAR4 are all activated by thrombin; PAR2 is the only PAR that is not [33]. The fITF:FVIIa:FXa complex can directly cleave both PAR1 and PAR2, and fITF:FVIIa can cleave PAR2. Signaling by the fITF:FVIIa:FXa complex is supported by the endothelial protein C receptor (EPCR), enabling PAR signaling, and is required for the induction of proinflammatory genes [34, 35]. In contrast, fITF:FVIIa elicits MAPK signaling through PAR2, not PAR1, and also promotes calcium mobilization, activation of Src family kinases, and activation of other pathways like PI3K, JAK/STAT, and β-catenin [36–43]. However, studies show that PARs often exist in close proximity to each another and are capable of forming homodimers and heterodimers [44]. Furthermore, cleaved PAR2 can transactivate PAR1, and vice versa [44, 45]. Thus, both PAR1 and PAR2 signaling are closely linked, and can potentially lead to each other’s activation by proxy.

Once PARs are cleaved, they can transactivate nearby membrane-bound receptor tyrosine kinases (RTKs) [46]. Such transactivation could occur via one of two mechanisms: (i) ligand-independent recruitment of non-tyrosine kinases; (ii) a “triple membrane passing signal” mechanism wherein membrane-bound matrix metalloproteases are activated, leading to receptor ligand shedding, in turn causing paracrine and/or autocrine RTK activation [47]. fITF:FVIIa cleavage of PARs causes transactivation of multiple RTKs, including EGFR, PDGFRβ, and IGF-1R [48–51]. Because this generally happens within minutes, and does not depend on secreted ligand, fITF:FVIIa transactivation of RTKs through PARs is mostly via the former, ligand-independent mechanism. In fact, fITF:FVIIa activation of PAR2 leads to RTK phosphorylation via a ligand-independent, Src-dependent intracellular pathway [48–51]. This means that even when extracellular ligands for RTKs are absent or when cells are in the presence of extracellular RTK inhibitors, fITF:FVIIa may still activate those RTKs through PAR2. Even though intracellular activation of RTKs via fITF may confer resistance to RTK small molecule inhibitors, anti-RTK antibodies are often still clinically effective [52].
A lot of TF’s non-coagulant effects are dependent on integrins. These are heterodimeric transmembrane receptors that function as adhesion molecules for both cell-cell and cell-extracellular matrix (ECM) interactions, and mediate a variety of biological processes that include survival, proliferation, stemness, and migration [53]. There are 24 integrins, each being composed of various combinations of α and β subunits. Integrins can assume three conformation states, including bent (inactive), extended (intermediate affinity), or extended with open conformation (high affinity) [54]. f TF directly interacts with α3, α6, and β1 integrin subunits [55, 56], and f TF: FVIIa associates with β1 subunits in the active conformation, thus inducing the internalization of the TF:FVIIa-β1 integrin complex via GTPase Arf6 [57]. Although PAR2 activation enhances the affinity of f TF:FVIIa to β1 integrins, blocking PAR2 activation is not sufficient to prevent f TF:FVIIa binding to β1 integrins [56].

In addition to f TF:FVIIa cleaving PAR2, it also cleaves receptors in the Eph RTK family [58]. The Eph RTK family includes 14 members separated into nine EphA and five EphB receptors, that govern cell proliferation, differentiation, and mobility [59, 60]. f TF:FVIIa directly cleaves both EphB2 and EphA2, independent of PAR2.
activation or the flTF:FVIIa:FXa ternary complex [58]. The consequences of this are the subject of ongoing investigation.

The flTF cytoplasmic domain plays an especially important role in non-coagulant signaling. It serves as a scaffold for molecules involved in adhesion, migration, and cytoskeleton organization, such as actin-binding protein-280 (ABP-280). TF localizes to lamellipodia, which are created by cytoskeletal protein actin projections on the invasive edges of cells [61–63]. TF binding of ABP-280 may also positively regulate its release via flTF-MVs [64], resulting in paracrine signaling [65]. The flTF cytoplasmic domain is phosphorylated at Ser253 by protein kinase C (PKC) and at Ser258 by p38 MAPK [28, 31, 36, 66]. Such phosphorylation promotes the physical association of flTF with αβ1 integrins, thereby enhancing cell migration on laminin 5 [55]. This flTF cytoplasmic domain interacts with the PI3K regulatory subunit p55 and is required for flTF-induced interleukin-8 (IL-8) expression and resultant angiogenesis [57]. The cytoplasmic domain of flTF does not affect the procoagulant activity of flTF, nor does it alter the proteolytic activation of PAR2 by flTF:FVIIa [57, 67–69]. However, once the flTF cytoplasmic domain is phosphorylated, it inhibits PAR2-dependent angiogenesis [55, 70]. Interestingly, mice lacking the flTF cytoplasmic domain do not die in utero, unlike TF-deficient mice, and flTF:FVIIa association with β1-integrin does not require the cytoplasmic domain [57, 71].

Whereas flTF can either remain anchored within the cell membrane or be secreted, asTF lacks the transmembrane domain and is only secreted. Although asTF is not very pro-coagulant, it does have non-hemostatic functions. For example, asTF is a powerful pro-angiogenic molecule via non-proteolytic ligation of both αβ1 and αβ3 integrins, leading to increased FAK, PI3K/AKT, and MAPK signaling [16, 72]. In contrast to flTF, asTF can bind integrins without the help of FVII [16].

Multiple growth factors and cytokines induce TF expression. For example, hepatocyte growth factor (HGF) upregulates TF by activating Met in a Src kinase-dependent manner [82]. Other growth factors, including basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF)-BB, PDGF-CC, PDGF-AA, bone morphogenetic protein-7 (BMP-7), transforming growth factor-β (TGF-β), and vascular endothelial growth factor (VEGF) can also increase TF [83–90]. During inflammation, TF can be upregulated by a variety of cytokines and signaling molecules, including interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), IL-6, IL-1β, IL-33, and histamine [91–99]. Activated T lymphocytes release CD40-ligand (CD40L), which also induces TF [100]. Conversely, the anti-inflammatory cytokines IL-4, IL-10, and IL-13 all suppress TF [101–103].

In cancer, TF expression can be directly driven by oncogenic events (Fig. 3). For example, mutations in the tumor suppressor TP53 and proto-oncogene KRAS activate MAPK and PI3K/AKT signaling pathways, in turn stimulating TF expression [104, 105]. In glioma, amplification of epidermal growth factor receptor (EGFR) and/or its constitutively active mutant form, EGFRVIII, promotes the expression of TF, PARs, and ectopic synthesis of FVII, thus sensitizing the cells to TF-mediated signaling [106]. EGFR-mediated TF expression depends on activator protein-1 (AP-1) and is associated with c-Jun NH(2)-terminal kinase (JNK) and JunD activation [107]. Blocking EGFR signaling in human carcinoma and glioma cells diminishes TF expression [108]. Loss of the tumor suppressor Pten or E-cadherin also leads to TF upregulation [109–111]. In neuroblastoma, MYCN amplification positively correlates with TF [112].

Cancer-associated hypoxia also stimulates TF expression via canonical hypoxia-associated signaling molecules, including hypoxia-inducible factor 1-alpha, early growth response gene-1 (Egr-1), Cyre61, and VEGF [113, 114]. In glioblastoma (GBM), hypoxia is sufficient to increase TF production in cultured GBM cells, and tumor cells surrounding necrotic, hypoxic zones stain strongly for TF [109, 115].

In contrast, we found that gliomas with mutations in isocitrate dehydrogenase 1 or IDH2 (collectively “IDHmut”) hypermethylate the early coding region of F3 and suppress its transcription, correlating with less flTF-MV production, less risk of VTE, and less aggressive behavior [116, 117]. This appears to be unique to IDHmut gliomas, as other IDHmut cancers, such as cholangiocarcinoma and acute myeloid leukemia, neither hypermethylate F3 nor suppress TF production [51, 116].

Pathophysiological effects of TF signaling

While TF clearly has critical roles to play in normal hemostatic and non-hemostatic cell functions, such
activities can also greatly contribute to the malignant behavior of cancer. Elevated TF is a common feature of many cancers, and generally correlates with worse patient survival (Fig. 4) [6]. Here, we will discuss some of the key studies examining the pathological consequences of TF expression in cancer, including effects on angiogenesis, invasion, cell survival, metastasis, and maintenance of cancer stem-like cell (CSC) populations.

**Tumor angiogenesis**

fTf-FVIIa activation of PAR2 triggers downstream transcription of several proangiogenic genes, including VEGF, IL8, FGF2, and CXCL1 [38, 118–120]. The cytoplasmic domain of fTf is important for controlling VEGF expression, and its phosphorylation correlates with VEGF expression in cancer [121–123]. Consistent with this, fTf deletion results in vascular failure during embryogenesis, and just deleting the fTf cytoplasmic domain is sufficient to suppress VEGF production [121, 122, 124]. Of note, although fTf deletion in mice results in vascular abnormalities, it does not phenocopy VEGF deletion [125]. Positive correlations between fTf and vascular density have been reported in cancers of the brain, pancreas, prostate, large bowel, lung, and breast [126–131]. This seems to be primarily through PAR2, because although some have also implicated PAR1 in blood vessel growth, PAR1-deficient mice show normal wound healing and postnatal angiogenesis [132–135]. Studies in PAR1- and PAR2-deficient mice further support the notion that signaling through PAR2, but not PAR1, is important for tumor angiogenesis [136].

Like fTf, elevated expression of aTf increases the expression of multiple genes that promote angiogenesis like VEGF, AREG, and EFEMP1 [23], and at least part of aTf-induced cancer angiogenesis is dependent on ligation of β1 and β3 integrins [16, 137]. Furthermore, aTf does not require FVIIa to induce angiogenesis [16]. High expression of aTf correlates with worse patient survival in lung and gastric cancer [138, 139].
Proliferation, cell survival, and apoptosis

Both fITF and aSTF can increase the proliferation of many different kinds of cancer, though perhaps by different mechanisms [140]. In colon cancer cells, fITF: FVIIa activates PAR2, leading to increased proliferation through the PKCα and ERK1/2 pathways [141, 142]. In breast cancer cells, the pro-proliferative effect of aSTF depends on β1 integrin [143]. However, the response of cancers to TF likely depends on their molecular background. For example, we found that GBM cells with driver mutations in EGFR are far more dependent on endogenous TF for cell proliferation than GBM cells with driver mutations in NFI [116].

fITF has a number of anti-apoptotic effects in cancer cells, including activation of PI3K, AKT, and JAK/STAT5 signaling pathways; suppression of death-associated protein kinase-1; and upregulation of BclXL [144–148]. As a result, fITF can prevent anoikis (Greek for “homeless”), a form of apoptosis that is induced by the lack of anchorage-dependent survival signaling caused by loss of surrounding extracellular matrix [143, 146, 149].

Cancer stem-like cells

Special subpopulations of cells within cancer are capable of self-renewal. These cells are commonly referred to as cancer stem-like cells (CSCs), and they contribute to therapy resistance, recurrence, and distant metastasis [150]. Our data, and that of others, indicate that TF contributes to the CSC phenotype [151]. For example, TF is positively correlated with well-known markers of CSC like CD44 and CD133, and is enriched on CSCs compared to cancer cells without self-renewing capacity [152–156]. In conditional knock-down experiments, lack of TF can prevent the growth of some xenografted cancers for prolonged periods of time, followed by abrupt and rapid growth when TF expression is restored [157]. Conversely, others found that TF may not be a regulator of CSC populations in all cancer types. Schaffner et al. showed that EPCR negative cells and receptor blocking EPCR antibodies reduced breast cancer stem cell populations, whereas TF expression did not alter the CSC phenotype [158].

Invasion and metastasis

Metastasis is a Greek word meaning “displacement” and is the result of multiple cellular processes working together to allow cancer cells to invade normal tissue beyond the original tumor site, survive while traveling through the blood or lymphatic system, and form a new tumor in a distant site. TF is prominently expressed at the invasive edge of tumors and positively correlates with invasiveness in cancers from a variety of organs, including the liver, breast, pancreas, and lung [159–162]. TF expression is also up to 1000-fold greater in metastatic cells than in non-metastatic cells [163]. An unbiased shRNA screen showed that TF is one of the most powerful drivers of metastasis in osteosarcoma [164]. Such correlative findings have been verified by functional studies in vivo [23, 163, 165].

The mechanisms underpinning TF’s effects on invasion and metastasis mostly resemble those already noted in other pro-malignant functions. The pro-invasive effects of fITF on cancer cells appear to depend on the cytoplasmic domain, as expression of mutant fITF constructs that lack the cytoplasmic domain are far less metastatic [166, 167]. The cytoplasmic domain of fITF promotes invasion by activating the GTPase Rac1 and p38 MAPK, which interact with actin filaments and cause extension of filopodia and lamellipodia [61]. fITF-mediated activation of PAR2 also recruits actin-binding protein to the cytoplasmic domain of fITF, and promotes cytoskeleton reorganization and cell motility by activating MAPK and cofillin pathways [62, 63, 168]. Activated PAR2 stabilizes and increases β-catenin expression [169], and in glioma, the pro-invasive effects of fITF: FVIIa is dependent in part on β-catenin [116]. However, fITF-β1 integrin interaction promotes cell migration when the fITF cytoplasmic domain is phosphorylated [55], suggesting the requirement of PAR2 activation. In contrast, aSTF can increase cell motility by directly binding and activating β1 integrins [170].

The release of fITF-MVs by tumors can also promote metastasis via paracrine signaling within the tumor microenvironment and at distal sites. fITF-MVs are elevated in the plasma of cancer patients [171, 172] and can activate PAR1 and PAR2 on nonmalignant cells [173, 174]. Endothelial cells that are stimulated with fITF-MVs express increased adhesion molecules and secrete pro-inflammatory molecules that can recruit pro-tumor monocytes, establishing a pre-metastatic niche for circulating cancer cells [173, 175].

In addition to the aforementioned suppression of anoikis, fITF-mediated activation of the coagulation pathway is important once cancer cells enter the bloodstream. Two monoclonal inhibitory antibodies were developed to study the role of blood coagulation in metastasis. The first, mAb-10H10, blocks fITF:FVIIa-mediated PAR2 activation without any significant effect on coagulation. The second, mAb-5G9, blocks the formation of the fITF: FVIIa:FXa complex, thereby inhibiting stimulation of both PAR1 and PAR2, as well as impairing coagulation [176]. Using both antibodies in a model of patient-derived breast cancer xenografts, Versteeg et al. showed that, whereas mAb-10H10 inhibited primary tumor growth, mAb-5G9 inhibited its metastatic spread [56]. Palumbo et al. suggested that fITF further supports tumor metastasis via thrombin-dependent and platelet-
dependent mechanisms that prevent natural killer cell clearance of cancer cells [177]. In sum, both TF-mediated thrombin generation and TF-mediated intracellular signaling contribute to distal metastasis.

**Tissue factor as a target for cancer therapy**

Because TF plays multiple roles in the malignant behavior of cancer, blocking its signaling might improve cancer treatment. A direct inhibitor of TF:FVIIa, recombinant nematode anticoagulant protein c2 (rNAPc2), has been shown to reduce tumor growth in preclinical models of colorectal cancer and melanoma [178, 179]. These findings promoted a clinical trial to test the safety of rNAPc2 to treat colon cancer (Clinical-Trial.gov, ID NCT00443573); however, this study was suspended, and no results were published. rNAPc2 has a narrow therapeutic window, with a high risk of bleeding complications [180], and this could likely explain why the rNAPc2 trial was suspended. Although directly targeting TF disrupts normal hemostasis and increases risk of uncontrollable hemorrhage, there are ways of blocking non-hemostatic aspects of TF activity. For example, the clinical grade formulation of the mAb-10H10 (CNTO 2559) does not interfere with hemostasis and has inhibited breast cancer growth in mice [181].

As discussed above, one of the primary targets of TF is the PAR signaling nexus. Because TF activates PARs independently of its role in coagulation, targeting PARs could limit many of the pro-cancer effects of TF without the dangerous side effects of direct TF inhibition. Small molecule PAR inhibitors have therefore been tested as potential cancer therapeutics. The PAR2 antagonist, GB88, and its derivatives, block PAR2 activation and reduced inflammation, yet these inhibitors have low IC$_{50}$ and solubility, limiting their effectiveness in vivo [182–184]. Furthermore, for unclear reasons, GB88 blocks only certain PAR2-mediated signaling pathways, such as Ca$^{2+}$ mobilization, but not MAPK signaling [185]. Recently, a new PAR2 antagonist, I-191, was developed that has a much higher IC$_{50}$ and solubility and blocks both Ca$^{2+}$ mobilization and MAPK signaling [182]. Two PAR1 inhibitors exist, atopaxar and vorapaxar, and both inhibit cancer progression in preclinical models [186]. An additional approach for blocking PAR signaling involves the use of cell-penetrating peptide antagonists termed “pepducins” [187]. PAR1-targeting pepducin P1pal-7 blocked lung cancer cell migration and inhibited lung tumor growth by 75% [188]. For excellent in-depth reviews on targeting PARs, see Ramachandran et al. and Hamilton et al. [185, 189]. However, while PAR inhibitors seem to be well-tolerated in animal models, it remains to be determined whether targeting PAR1 or PAR2 will prove effective in cancer patients.

fTF requires FVII and FX complex formation for efficient proteolytic signaling. Because FVII and FX are vitamin K-dependent, their expression can be reduced by using vitamin K antagonists, like warfarin, which has been shown to suppress tumorigenesis [190–192]. Warfarin also blocks the growth and spread of pancreatic cancer by inhibiting signaling of another RTK, Axl [193]. An FXa inhibitor, rivaroxaban, did not directly affect the growth of TF-positive pancreatic cancer xenografts in immunodeficient mice [194], but did suppress tumor growth in an immunocompetent setting that was partially dependent on reprogramming tumor-associated macrophages [195]. A selective small molecule inhibitor of FVIIa, PCI-27483, inhibited tumor growth in preclinical models [196], although combining it with gemcitabine was not clearly superior to gemcitabine alone in a phase 2 clinical trial against pancreatic cancer [197].

Because TF is highly expressed on the surface of many kinds of cancer cells, some have investigated the ability of TF-specific antibody:drug conjugates to deliver tumoricidal drugs. One prominent example is a human anti-TF antibody conjugated to the cytotoxic agent monomethyl auristatin E (TF-011-MMAE) [198]. TF-011-MMAE has suppressed tumor growth and metastasis in a variety of preclinical cancer models, even those expressing relatively low amounts of TF, without significant effect on coagulation, and showed better intracellular internalization than antibody:drug conjugates targeting EGFR or HER2 [198–200]. TF-011-MMAE, now renamed HuMax-TF-ADC, has undergone multiple phase 1 trials demonstrating its safety and is currently undergoing a multicenter phase 2 clinical trial for safety and efficacy against cervical cancer and solid tumors (ClinicalTrial.gov, ID: NCT03438396, NCT03485209).

Hu et al. have developed chimeric antibody-like homodimers that consist of FVII fused to the Fc domain of IgG1 [201]. These immunoconjugates, which are named “ICONs,” target TF-expressing tumors, and induce both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity [202–204]. ICONs lack procoagulant activity due to the elimination of Lys$_{341}$, and when administered intravenously, inhibit the growth of melanoma, prostate, and head and neck tumors [201, 202, 205]. Because first generation ICONs are relatively large molecules (210 kDa), their bioavailability within solid tumors is questionable. A smaller (100 kDa), more efficient second-generation ICON, L-ICON1, is now being evaluated in preclinical studies [206].

A rapidly emerging immunotherapy strategy for treating cancer is chimeric antigen receptor (CAR)-modified T cells (CAR T) [207, 208]. To date, CAR T therapy against hematopoietic cancers has met with some success [209], but whether it has real potential against solid tumors is debatable. One limiting factor of CAR T in solid tumors is finding suitable antigens to target [207,
Zhang et al. developed human T cells modified to express the light chain of mouse FVII, since it binds strongly to both human and mouse TF [210]. These cells, termed TF-CAR T cells, reduced tumor growth and metastasis in NOG mice with human lung cancer xenografts [210]. However, off-target toxicity is one of the main limiting factors of CAR T therapy, so although the authors found no toxicity in mice from the TF-CAR T cells [210], it still remains to be determined whether this approach will have any off-target toxicity in humans.

Since the secreted TF isoform, asTF, also plays a prominent role in cancer malignancy but is only minimally procoagulant, it can be directly targeted without worrying about bleeding. Bogdanov et al. developed an asTF-specific neutralizing antibody termed “RabMab1” [15, 143, 170]. RabMab1 is capable of blocking asTF from binding to integrins and inhibits pancreatic and breast cancer growth in vivo [143, 170]. Other than RabMab1, asTF-specific therapies are scarce. However, other asTF-directed approaches could potentially include inhibitory RNAs that specifically target the unique exons 4-6 spliced sequence or by blocking splicing regulatory proteins that produce asTF [211].

Conclusion and future perspectives
It is now clear that TF has a wide range of activities beyond thrombosis, and that these activities are utilized by cancers to increase their malignancy. Further insights into TF signaling, and how to block pro-cancer effects while retaining its hemostatic capacity, may lead to more effective therapies against the pro-tumor effects of TF.

Abbreviations
asTF: Alternatively spliced tissue factor; bFGF: Basic fibroblast growth factor; BMP: Bone morphogenenic protein; CAR T: Chimeric antigen receptor-modified T cells; FvII: Coagulation factor VII; FIX: Coagulation factor IX; FX: Coagulation factor X; CSC: Cancer stem-like cells; EGFR: Epidermal growth factor receptor; EPCR: Endothelial protein C receptor; FvIII: Full-length tissue factor; GBM: Glioblastoma; HGF: Hepatocyte growth factor; ICAMs: Immunocunjugates; INF-γ: Interferon-γ; MVs: Microvesicles; nNAPC2: Nematode anticoagulant protein c2; PAR: Protease-activated receptor; PKC: Protein kinase C; PDGF: Platelet-derived growth factor; RTKs: Receptor tyrosine kinases; TF: Tissue factor; TGF-β: Transforming growth factor-β; TNF-α: Tumor necrosis factor-α; VEGF: Vascular endothelial growth factor; VTE: Venous thromboembolism

Acknowledgements
None

Authors’ contributions
D.U. and C.H: conceptualized and wrote the manuscript. D.U. created the figures. All authors read and approved the final manuscript.

Funding
D.U. was supported by the grant F32CA216996 from the National Institutes of Health (NIH). C.H. was supported by NIH grants R01NS102669, R01NS117104, the Northwestern University SPORE in Brain Cancer P50CA221747, and the Lou and Jean Malnati Brain Tumor Institute.

Availability of data and materials
Not applicable for this review.

Competing interest
The authors declare no competing interests.

Ethics approval and consent to participate
Not applicable for this review.

Consent for publication
Not applicable for this review.

Author details
1Department of Neurological Surgery, Northwestern University, 303 East Superior St, Chicago, IL 60611, USA. 2Department of Pathology, Northwestern University, Chicago, IL 60611, USA.

Received: 1 June 2020 Accepted: 2 July 2020
Published online: 14 July 2020

References
1. Morawitz P. Die Chemie der Blutgerinnung. Ergebnisse der Physiologie. 1905;4(1):307–422.
2. Boulton F. A hundred years of cascading - started by Paul Morawitz (1879-1936), a pioneer of haemostasis and of transfusion. Transfus Med. 2006;16(1):1–10.
3. Bachill M. Esther. Historical review. British Journal of Haematology. 2000;110(2):248–55.
4. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. The American journal of pathology. 1989;134(5):1087–97.
5. Osterud B, Bjorklid E. Sources of tissue factor. Seminars in thrombosis and hemostasis. 2006;32(1):111–23.
6. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119(4):924–32.
7. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circulation research. 2011;108(10):1284–97.
8. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(3):1499-506.
9. Falanga A. Thrombophilia in cancer. Seminars in thrombosis and hemostasis. 2005;31(1):104–10.
10. Heit JA, O’Fallon WM, Petterson TM, Loehne CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162(1):1245–5.
11. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35(1-2):103–10.
12. Varki A. Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723–9.
13. Devaere M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114(12):2367–74.
14. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315(20):1650–9.
15. Bogdanov VY, Balasubramanian V, Hatchcock J, Veile O, Lieb M, Nernson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nature medicine. 2003;9(4):458–62.
16. van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, et al. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A. 2009;106(46):19497–502.
17. Muller YA, Utlsch MH, de Vos AM. The crystal structural of the extracellular domain of human tissue factor refined to 1.7 A resolution. J Mol Biol. 1996;256(1):144–59.
18. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thrombosis research. 1996;61(1):1–41.
19. Pendurthi UR, Ghosh S, Mandal SK, Rao LV. Tissue factor activation: is disulfide bond switching a regulatory mechanism? Blood. 2007;110(12):3900–8.
20. Censarek P, Bobbe A, Grandoch M, Schor K, Weber AA. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thrombosis and haemostasis. 2007;97(1):11–4.
42. Versteeg HH, Yrsten VY, Versteeg HH. Interplay between alternatively spliced tissue factor and full length tissue factor in modulating coagulant activity of endothelial cells. Thrombosis research. 2017;1561–7.

41. Fang J, Gu L, Zhu N, Tang H, Alvarado CS, Zhou M. Tissue factor/FVIIa–activates Bcl-2 and prevents doxorubicin-induced apoptosis in MDA-MB-231 cells. BMC cancer. 2009;8:69.

40. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Activation of the tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation. The Journal of biological chemistry. 2002;277(30):27065–72.

39. Camerer E, Rottingen JA, Gjernes E, Larsen K, Skartlien AH, Iversen JG, et al. Localization of tissue factor in actin-filament-rich membrane areas of tumor cells. Thrombosis and haemostasis. 2004;92(1):57–67.

38. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. Scientific reports. 2019;9(1):8946.

37. Liang HP, Kerschen EJ, Hernandez I, Basu S, Zogg M, Botros F, et al. EPCR–factor VIIa signalling in HaCaT cells. Thrombosis and haemostasis. 2004;92(1):74–8.

36. Eriksson O, Ramstrom M, Hornaeus K, Bergquist J, Mokhtari D, Siegbahn A. Expression of tissue factor in macrophages and other cell types. Thrombosis and haemostasis. 2016;115(2):299–309.

35. Liang HP, Kerschen EJ, Hernandez I, Basu S, Zogg M, Botros F, et al. EPCR–factor VIIa signalling in HaCaT cells. Thrombosis and haemostasis. 2004;92(1):74–8.

34. Eriksson O, Ramstrom M, Hornaeus K, Bergquist J, Mokhtari D, Siegbahn A. Expression of tissue factor in macrophages and other cell types. Thrombosis and haemostasis. 2016;115(2):299–309.

33. Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J. 2019;17(4).

32. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying the tissue factor cytoplasmic domain. The Journal of biological chemistry. 1992;267(6):3561–4.

31. Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and activity of natural and recombinant tissue factor. The Journal of biological chemistry. 2010;285(5):3371–82.

30. Zöchger TF, Roy S, Vehar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. The Journal of biological chemistry. 1993;268(26):18455–54.

29. Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and activity of natural and recombinant tissue factor. The Journal of biological chemistry. 2010;285(5):3371–82.

28. Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and activity of natural and recombinant tissue factor. The Journal of biological chemistry. 2010;285(5):3371–82.

27. Krudysz-Amblo J, Jennings ME 2nd, Mann KG, Butenas S. Carbohydrates and activity of natural and recombinant tissue factor. The Journal of biological chemistry. 2010;285(5):3371–82.

26. Stone MJ, Ruf W, Miles DJ, Edgington TS, Wright PE. Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization. Biochem J. 1995;310(1):2105–14.

25. Paborsky LR, Harris RJ. Post-translational modifications of recombinant human tissue factor. Thrombosis research. 1990;60(5):367–76.

24. Unruh D, Sagin F, Adam M, Van Dreden P, Woodhams BJ, Hart K, et al. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may predict aggressive tumor phenotype. Annals of surgical oncology. 2015;22(Suppl 3):S1206–11.

23. Unruh D, Turner K, Srinivasan R, Kocaturk B, Qi X, Chu Z, et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. International journal of cancer. 2014;134(1):9–20.

22. Boing AH, Hau CM, Sturk A, Nieuwland R. Human alternatively spliced tissue factor is not secreted and does not trigger coagulation. J Thromb Haemost. 2006;4(8):1423–6.

21. Unlu B, Bogdanov VY, Versteeg HH. Interplay between alternatively spliced tissue factor and full length tissue factor in modulating coagulant activity of endothelial cells. Thrombosis research. 2017;1561–7.

20. Fox BM, Alicki JS, Srinivasan R, Srinivasan R, Srinivasan R, Srinivasan R. alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. International journal of cancer. 2014;134(1):9–20.

19. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Activation of the tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation. The Journal of biological chemistry. 2002;277(30):27065–72.
85. Gebhard C, Akhmedov A, Mocharla P, Angstenberger J, Sahbai S, Camici GG, Kamimura M, Bea F, Akizawa T, Katus HA, Kreuzer J, Viedt C. Platelet-derived Corseaux D, Meurice T, Six I, Rugeri L, Ezekowitz MD, Rouvier P, et al. Basic Provencal M, Labbe D, Veitch R, Boivin D, Rivard GE, Sartelet H, et al. c-Met 76. Witkowski M, Saffarzadeh M, Friebel J, Tabaraie T, Ta Bao L, Mészáros K, Aberle S, Dedrick R, Machovich R, Horwitz A, Birr C, et al. Monocyte Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor Melis E, Moons L, De Mol M, Herbert JM, Mackman N, Collen D, et al. Belting M, Dorrell MI, Sandgren S, Aguilar E, Alamed J, Dorfleutner A, et al. Carson SD, Bromberg ME. Tissue factor encryption/de-encryption is not Unruh and Horbinski Journal of Hematology & Oncology
108. Milosevic CC, Yu JL, Mackman N, Micaleff J, Anderson GM, Guha A, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer research. 2008;68(4):10068–76.
109. Yong R, Post DE, Pieper RO, Duden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer research. 2005;65(4):1406–13.
110. Fang J, Tang H, Xia LH, Wei WN, Hu Y, Song SJ. Regulation of tissue factor expression by anti-angiogenic PTEN in human neuroblastoma cell line. Zhonghua Xue Ye Xue Za Zhi. 2007;28(6):363–6.
111. Regina S, Valentin JB, Lachot S, Lemaire E, Rollin J, Gruel Y. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin Chem. 2006;52(10):1834–42.
112. Shenefi LM, Hassan TH, Zakaria M, Fathy M, Eshak EA, Bebars MA, et al. Tissue factor expression predicts outcome in children with neuroblastoma: a retrospective study. Oncology letters. 2019;18(6):6347–54.
113. Sun L, Liu Y, Lin S, Shang J, Liu J, Li J, et al. Early growth response gene-1 and hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of tissue factor. Acta Oncol. 2013;52(4):842–51.
114. Eisenreich A, Zakrzewicz A, Huber K, Thierbach H, Pepke W, Goldin-Lang P, et al. Activation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. Oncology reports. 2013;30(1):462–70.
115. Monteiro RQ, Lima LG, Goncalves NP, MR DES, Leal AC, Demasi MA, et al. Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model. Oncology letters. 2016;12(1):315–322.
116. Unruh D, Mirkov S, Way B, Drumm M, Lamanno J, Li YD, et al. Methylation-dependent tissue factor suppression contributes to the reduced malignancy of IDH1 mutant gliomas. Clin Cancer Res. 2018.
117. Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016.
118. Liu Y, Mueller BM. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochemical and biophysical research communications. 2006;344(4):1263–9.
119. Song HB, Park KD, Kim JH, Kim DH, Yu YS, Kim JH. Tissue factor regulates tumor angiogenesis of retinoblastoma via the extracellular signal-regulated kinase pathway. Oncology reports. 2011;27(6):2057–62.
120. Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM, et al. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer research. 2008;68(17):7219–27.
121. Signaevsky M, Hobbs J, Dorn J, Liu N, Soff GA. Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis. Seminars in thrombosis and hemostasis. 2008;34(2):161–9.
122. Wu M, Chen L, Xu T, Xu B, Jiang J, Wu C. Prognostic values of tissue factor and its alternatively splice variants in human gastric cancer tissues. Oncotarget. 2017;8(32):5317–45.
123. Rollin J, Regina S, Gruel Y. Tumor expression of alternatively spliced tissue factor is a prognostic marker in non-small cell lung cancer. J Thromb Haemost. 2010;8(3):607–10.
124. Leppert U, Eisenreich A. The role of tissue factor isoforms in cancer biology. International journal of cancer. 2015;137(4):597–593.
125. Hu L, Wu L, Zhuo H, Liu Y, Wu Y, et al. TF/VIIa/PAR2 promotes cell proliferation and migration via PI3KAlfha and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620. Tumour Biol. 2013;34(2):2573–81.
126. Wu B, Zhou H, Hu L, Wu Y, Yu Y. Involvement of PI3KAlpha activation in TF/VIIa/PAR2-induced proliferation, migration, and survival of colon cancer cell SW620. Tumour Biol. 2013;34(2):837–46.
127. Kocaturk B, Van den Berg YW, Tielken C, Mieog JS, de Krijff EM, Engels CG, et al. Alternatively spliced tissue factor factors promotes breast cancer growth in a beta1 integrin-dependent manner. Proc Natl Acad Sci U S A. 2013;110(28):11517–22.
128. Abeg M, Wickstrom M, Siebahn A. Simvastatin induces apoptosis in human breast cancer cells in a NF kappaB-dependent manner and abolishes the anti-apoptotic signalling of TF/VIIa and TF/VIIa FXa Thrombosis research. 2008;122(2):191–202.
129. Abeg M, Johnell M, Wickstrom M, Siebahn A. Tissue factor/FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPKi). Thrombosis research. 2011;127(2):141–148.
130. Horbinski C, Mojesky C, Kyprianou N. Live free or die: tales of homeless (cells) in cancer. The American journal of pathology. 2010;177(3):1044–52.
131. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol. 2012;44(12):2144–51.
132. Milosom C, Magnus N, Meehan B, Al-Nedawi K, Garnier D, Rak J. Tissue factor and cancer stem cells: is there a linkage? Arteriosclerosis, thrombosis, and hemostasis. 2008;28(12):2053–61.
133. Garin D, Milosom C, Magnus N, Meehan B, Weitz J, Yu J, et al. Role of the tissue factor pathway in the biology of tumor initiating cells. Thrombosis research. 2010;125(Suppl 2):S44–50.
134. Milosom C, Anderson GM, Weitz J, Rak J. Elevated tissue factor procoagulant activity in CD133+ positive cancer cells. J Thromb Haemost. 2007;5(12):2550–2.
coagulation is essential for metastatic cell survival and premalignant niche establishment in mice. Blood. 2012;119(13):3164–75.

176. Huang M, Syed R, Stura EA, Stone MJ, Stefanko RS, Ruf W, et al. The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab SG9 and TF-G9 complex. J Mol Biol. 2019;488(5):723–34.

177. Palumbo JS, Talmage KE, Massari JV, LaJeunesse CM, Flick MJ, Kombrinck KW, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007;110(1):133–41.

178. Hembrough TA, Swartz GM, Papanathanassia A, Vasuk GP, Roe WE, Green SJ, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer research. 2003;63(12):2997–3000.

179. Zhao J, Aguilar G, Palencia S, Newton E, Abbo A. nAPC2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009;15(1):208–16.

180. Moons AH, Peters RJ, Bijvelds WR, Piek JJ, Prins MH, Vasuk GP, et al. Recombinant nitro-9-anticoagulant protein C2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. Journal of the American College of cardiology. 2003;41(12):2147–52.

181. D’Asti E, Anderson GM, Rak J. Inhibition of tissue factor signaling in breast tumor xenografts induces widespread changes in the microRNA expression profile. Biochemical and biophysical research communications. 2017;494(4):700–5.

182. Barry GD, Suen JY, Le GT, Cotterell A, Reid RC, Fairlie DP. Novel agonists and antagonists for human tissue factor activated receptor 2. Journal of medicinal chemistry. 2010;53(20):7422–31.

183. Jiang Y, Yau MK, Lim J, Wu KC, Xu W, Suen JY, et al. A potent antagonist of tissue factor-activated receptor 2 that inhibits multiple signaling functions in human cancer cells. The Journal of pharmacology and experimental therapeutics. 2018;364(2):246–57.

184. Lohnr RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, et al. An antagonist of human tissue factor activated receptor-2 attenuates PAR signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2012;26(7):2877–87.

185. Hamilton JR, Trejo J. Challenges and opportunities in protease-activated receptor drug development. Annu Rev Pharmacol Toxicol. 2015;55:269–92.

186. Liu X, Yu J, Song S, Yue X, Li Q. Protease-activated receptor-1 (PAR-1) : a promising molecular target for cancer. Oncotarget. 2017;8(33):57334–45.

187. Covic L, Kuliopulos A. Targeting protease-activated receptor 1 for the treatment of inflammatory diseases. Curr Drug Targets. 2010;11(4):377–88.

188. Cisowski J, O’Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q, et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in vivo. The American journal of pathology. 2011;179(1):513–22.

189. MacMillan RD, Kuliopulos A. Protease-activated receptor 1–4: promises and challenges. Trends Pharmacol Sci. 2016;37(3):131–43.

190. Eichmann K, O’Connor MB, Kuliopulos A. Paracrine and intracrine activation of protease-activated receptor 1. In: Protease-activated receptors : biology and drug discovery. Annu Rev Pharmacol Toxicol. 2017;57:349–75.

191. Scholz A, Kasper F, Radtke F, Kalluri R. Tissue factor/factor VIIa complex. J Thromb Haemost. 2009;7(12):2169–73.

192. Graf C, Wilgenbus P, Pagel S, Pott J, Marini F, Reyda S, et al. Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Sci Immunol. 2019;4(39).

193. Pires JT, Thieman P, Loury D. PCI-27483, a small molecule inhibitor of Factor VIIa, inhibits growth of BxPC3 pancreatic adenocarcinoma xenograft tumors. Cancer research. 2008;68(Supplement):5669.

194. Ramanathan RK, Thomas GW, Khoraana AA, Shah S, Zhou C, Wong S, et al. A phase 2 study of PCI-27483, a Factor VIIa inhibitor in combination with gemcitabine for advanced pancreatic cancer. Oncology. 2019;96(4):217–22.
198. Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer research. 2014;74(4):1214–26.

199. Zhang X, Li Q, Zhao H, Ma L, Meng T, Qian J, et al. Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma. Oncotarget. 2017;8(35):59086–102.

200. de Goeij BE, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther. 2015;14(5):1130–40.

201. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A. 1999;96(14):8161–6.

202. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci U S A. 2001;98(21):12180–5.

203. Cheng J, Xu J, Duanmu J, Zhou H, Booth CJ, Hu Z. Effective treatment of human lung cancer by targeting tissue factor with a factor VII-targeted photodynamic therapy. Curr Cancer Drug Targets. 2011;11(9):1069–81.

204. Hu Z, Li J. Natural killer cells are crucial for the efficacy of Icon (factor VII/ human IgG1 Fc) immunotherapy in human tongue cancer. BMC Immunol. 2010;11:49.

205. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci U S A. 2000;97(16):9221–5.

206. Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, et al. Targeting tissue factor for immunotherapy of triple-negative breast cancer using a second-generation ICON. Cancer Immunol Res. 2018;6(6):671–84.

207. Subklewe M, von Bergwelt-Baildon M, Humpe A. Chimeric antigen receptor T cells: a race to revolutionize cancer therapy. Transfus Med Hemother. 2019;46(1):15–24.

208. Milliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19(1):1–18.

209. McHayleh W, Bedi P, Sehgal R, Solth M. Chimeric antigen receptor T-cells: the future is now. J Clin Med. 2019;8(2).

210. Zhang Q, Wang H, Li H, Xu J, Tian X, Yang J, et al. Chimeric antigen receptor-modified T cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice. Oncotarget. 2017;8(6):9488–99.

211. Lee SC, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nature medicine. 2016;22(9):976–86.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.